574 related articles for article (PubMed ID: 23234552)
1. Plasmodium kinases as targets for new-generation antimalarials.
Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Plasmodium kinome: the benefits of academia-industry synergy.
Leroy D; Doerig C
Trends Pharmacol Sci; 2008 May; 29(5):241-9. PubMed ID: 18394721
[TBL] [Abstract][Full Text] [Related]
3. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
4. Malarial kinases: novel targets for in silico approaches to drug discovery.
Bullard KM; DeLisle RK; Keenan SM
Methods Mol Biol; 2013; 993():205-29. PubMed ID: 23568473
[TBL] [Abstract][Full Text] [Related]
5. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
Qidwai T; Khan F
Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
[TBL] [Abstract][Full Text] [Related]
6. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
Tuteja R
FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium falciparum.
Hoen R; Novoa EM; López A; Camacho N; Cubells L; Vieira P; Santos M; Marin-Garcia P; Bautista JM; Cortés A; Ribas de Pouplana L; Royo M
Chembiochem; 2013 Mar; 14(4):499-509. PubMed ID: 23444099
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum protein kinase as a potential therapeutic target for antimalarial drugs development.
Mahmud F; Lee PC; Abdul Wahab H; Mustaffa KMF; Leow CH; Azhar R; Lai NS
Trop Biomed; 2020 Sep; 37(3):822-841. PubMed ID: 33612795
[TBL] [Abstract][Full Text] [Related]
9. Proteases of malaria parasites: new targets for chemotherapy.
Rosenthal PJ
Emerg Infect Dis; 1998; 4(1):49-57. PubMed ID: 9452398
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
12. Applying chemical genetic tools to the study of phospho-signalling pathways in malaria parasites.
Mitcheson DF; Tobin AB; Alam MM
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1650-6. PubMed ID: 26143498
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents.
Huang W; Hulverson MA; Zhang Z; Choi R; Hart KJ; Kennedy M; Vidadala RSR; Maly DJ; Van Voorhis WC; Lindner SE; Fan E; Ojo KK
Bioorg Med Chem Lett; 2016 Nov; 26(22):5487-5491. PubMed ID: 27780638
[TBL] [Abstract][Full Text] [Related]
15. Threonine peptidases as drug targets against malaria.
Tschan S; Mordmüller B; Kun JF
Expert Opin Ther Targets; 2011 Apr; 15(4):365-78. PubMed ID: 21281254
[TBL] [Abstract][Full Text] [Related]
16. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.
Bueno JM; Herreros E; Angulo-Barturen I; Ferrer S; Fiandor JM; Gamo FJ; Gargallo-Viola D; Derimanov G
Future Med Chem; 2012 Dec; 4(18):2311-23. PubMed ID: 23234553
[TBL] [Abstract][Full Text] [Related]
17. Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria.
Makanga M; Bray PG; Horrocks P; Ward SA
Proteomics; 2005 May; 5(7):1849-58. PubMed ID: 15832369
[TBL] [Abstract][Full Text] [Related]
18. Strategies to reverse drug resistance in malaria.
Egan TJ; Kaschula CH
Curr Opin Infect Dis; 2007 Dec; 20(6):598-604. PubMed ID: 17975410
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial drug discovery: targeting protein kinases.
Doerig C; Meijer L
Expert Opin Ther Targets; 2007 Mar; 11(3):279-90. PubMed ID: 17298288
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium falciparum pyruvate kinase as a novel target for antimalarial drug-screening.
Chan M; Tan DS; Sim TS
Travel Med Infect Dis; 2007 Mar; 5(2):125-31. PubMed ID: 17298920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
